Pancreatic Cancer Research

ResearcherVA Connecticut Healthcare SystemNo recent work listed

Jia Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1517-4946; OpenAlex author ID A5101632063. Sources: OpenAlex.

Their work

Papers
4 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
10
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: 2 papers · 2015: none · 2016: none · 2017: none · 2018: 1 paper

Papers 4

  1. Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience. Co-author DOI 10.1186/s12885-018-4605-1↗
  2. First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients with advanced pancreatic cancer. First author DOI 10.1007/s00280-013-2359-7↗
  3. Role of neoadjuvant therapy in management of pancreatic cancer. Co-author DOI 10.6092/1590-8577/2695↗
  4. Locally advanced pancreatic adenocarcinoma: are we making progress?. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011. Co-author PMID 21737893↗

Closest collaborators

The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Muhammad Wasif Saif · 3 shared papers, 2011–2014 · strength 0.17
  2. Danielle C. Glassman · 1 shared paper, 2018 · strength 0.08
  3. Anna M. Varghese · 1 shared paper, 2018 · strength 0.08
  4. Eileen Mary O'Reilly · 1 shared paper, 2018 · strength 0.08
  5. Kenneth H. Yu · 1 shared paper, 2018 · strength 0.08
  6. Lynne A. Lamb · 1 shared paper, 2014 · strength 0.04
  7. Kristin Kaley · 1 shared paper, 2014 · strength 0.04
  8. Yung‐Chi Cheng · 1 shared paper, 2014 · strength 0.04
  9. John Ng · 1 shared paper, 2011 · strength 0.04
  10. John Allendorf · 1 shared paper, 2011 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.